Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

NCT01948180 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Insufficient enrollment rate

Conditions

Lymphoma, Extranodal NK-T-Cell
EBV

Interventions

BIOLOGICAL: baltaleucel-T

Sponsor

Cell Medica Ltd